# CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

> **NCT05774899** · PHASE1,PHASE2 · RECRUITING · sponsor: **Glenn J. Hanna** · enrollment: 32 (estimated)

## Conditions studied

- Adenoid Cystic Carcinoma
- Metastatic Adenoid Cystic Carcinoma
- Recurrent Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** CB-103
- **DRUG:** Abemaciclib
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05774899
- **Lead sponsor:** Glenn J. Hanna
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05774899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05774899, "CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05774899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*